Dr. Reddy's Laboratories announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary
endpoints in a Phase 1 study. This Phase 1 study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of Dr. Reddy's tocilizumab biosimilar candidate in
comparison to reference products.
The company is initiating a global Phase 3 study with the aim of comparing the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product in patients with moderate to severe active rheumatoid arthritis
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
